Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013
Long-Term Cognitive Function, Neuroimaging and Quality of Life in Primary CNS Lymphoma
Neurol 81:84-92, Doolittle, N.,et al, 2013
SMART Syndrome (Stroke-Like Migraine Attacks After Radiation Therapy) in Adult and Pediatric Patients
J Child Neurol 29:336-341, Armstrong, A.E.,et al, 2013
Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era
Am J Transplant 13:1512-1522, Evens, A.M.,et al, 2013
Neurosyphilis Orofacial Dyskinesia: The Candy Sign
MovDisord 28:246-247, Martinelli, P.,et al, 2013
Herpes Encephalitis During Natalizumab Tretament in Multiple Sclerosis
Mult Scler J 18:909-911, Kwiatkowski, A.,et al, 2012
Fatal Varicella-Zoster Virus Vasculopathy Associated with Adalimumab Therapy
Arch Neurol 69:1193-1196, Baek, W.,et al, 2012
Bright Tongue Sign in ALS
Neurol 79:1520, Fox, M.D. & Cohen, A.B., 2012
Mystery Case: Hypoglossal Nerve Palsy in Occipito-Temporal Pneumatization
Neurol 79:e109-e110, Renard, D.,et al, 2012
Clinicopathologic Conference, Squamous- Cell Carcinoma of the Tongue with Metastasis to Lungs, Liver, Bone of Skull, Trigeminal Nerve, Base of Skull, Pituitary Gland and Dura Matter. Infarcts of Cerebellum and Right Frontal Lobe.
NEJM 367:1136-1145, Case 29-2012, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
PML-IRIS in a patient treated with Brentuximab
Neurol 79:2075-2077, Geldern, G.,et al, 2012
Acute severe visual loss and a brainstem mass
Lancet 380:1790, Meleth, A.,et al, 2012
Clinicopathologic Conference, Glioblastonoma, WHO grade IV of IV, with Methylation of the MGMT Promoter
NEJM 366:2112-2120, Case 17-2012, 2012
Thrombotic Stroke and Myocardial Infarction with Hormonal Contraception
NEJM 366:2257-2266, Lidegaard, O.,et al, 2012
Clinicopathologic Conference, Villaret Syndrome (Ipsilateral Cranial Nerves and Cervical Sympathetic Fibers) due to a Carotid-Artery Dissection and an Associated Aneurysm
NEJM 366:2306-2313, Case 18-2012, 2012
Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas are Associated with Improved Survival Compared with Matched Controls
AJNR 33:1763-1770, Mong, S.,et al, 2012
Long-lasting Treatment Effect of Rituximab in MuSK Myasthenia
Neurol 78:189-193, Diaz-Manera,J.,et al, 2012
Anticoagulant Loses its Lustre
Lancet 379:301, Mullar,A., 2012
Natalizumab-Associated PML Identified in the Presymptomatic Phase Using MRI Surveillance
Neurol 78:507-508, Blair,N.F.,et al, 2012
Fatal PML Associated with Efalizumab Therapy
Neurol 78:458-467, Schwab,N.,et al, 2012
Syncope: A Rare Manifestation of a Common Condition
Lancet 379:866, Hogarth,A.,et al, 2012
Clinicalpathologic Conference, Vitamin B12 Deficiency due to Pernicious Anemia
NEJM 366:1626-1633, Case 13-2012, 2012
Peripheral Neuropathy after Hip Replacement Failure: Is Vanadium the Culprit?
Lancet 379:1676, Moretti,B.,et al, 2012
Call It as You See It Evolution of Bilateral Striatal Necrosis
Neurol 78:e123, Coon,E.A. & Patterson,M.C., 2012
Treatment of Behcets Disease
UpToDate, Jan, Smith, E.L. & Yazici, Y., 2012
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Black Tongue Due to Adrenocortical Insufficiency
Arch Dis Child 97:1033, de Benedictis, F.M.,et al, 2012
Addisons Disease
Contemp Clin Dent 3:484-486, Sarkar, S.B.,et al, 2012
Peri-ictal Pseudoprogression in Patients with Brain Tumor
Neuro Oncol 13:775-782, Rheims, S.,et al, 2011
The "Million Hearts" Initiative - Preventing Heart Attacks and Strokes
NEJM 365:e27, Frieden, T.R.,et al, 2011
Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
Arch Neurol 68:1156-1164, Clifford, D.B.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Hypereosinophilia in Patients with Multiple Sclerosis Treated with Natalizumab
Neurol 77:1561-1564, Abbas, M.,et al, 2011
Clinical Characteristics of Pediatric-onset Neuro-Behcet Disease
Neurol 77:1900-1905, Uludiz, D.,et al, 2011
Multiple Sclerosis-Quenching the Flames of Inflammation
Lancet 378:1759-1760, , 2011
Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011
Evidence-based Guideline: Clinical Evaluation and Treatment of Transverse Myelitis
Neurol 77:2128-2134, Scott, T.F.,et al, 2011
Lingual Hematoma After Thrombolytic Therapy
NEJM 364:e13, Vijayan,S. &Chase,A., 2011
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011
Incidence and Predictors of Myocardial Infarction After Transient Ischemic Attack: A Population-Based Study
Stroke 42:935-940, Burns,J.D.,et al, 2011
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Use and monitoring of low dose rituximab in myasthenia gravis
JNNP 82:659-663, Blum, S., et al, 2011
Metastatic spinal cord compression
BMJ 342:d2402, Quraishi, N. & Esler, C., 2011
Clinicopathologic Conference, hemophagocytic lymphohistiocytosis
NEJM 364:1259-1270, Case 10-2011, 2011
Are all IV thrombolysis exclusion criteria necessary? Being SMART about evidence-based medicine
Neurol 76:1780-1781, Tong, D., 2011
Late onset autism and anti-NMDA-receptor encephalitis
Lancet 378:98;378, Creten, C.,et al, 2011
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 69:1060-1062, Phan-Ba, R.,et al, 2011
Ischemic Stroke and Transient Ischemic Attack After Head and Neck Radiotherapy
Stroke 42:2410-2418, Plummer, C.,et al, 2011